Loading…
Loading…
The Fund seeks current income and long-term capital appreciation, consistent with prudent investment management.
Is BOND's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Bank of New York Mellon Corp lifted its stake in shares of Pimco Total Return ETF (NYSEARCA:BOND) by 43.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 56,923 shares of the exchange traded fund's stock after purchasing
Avior Wealth Management LLC trimmed its position in shares of Pimco Total Return ETF (NYSEARCA:BOND) by 27.4% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 27,393 shares of the exchange traded fund's stock after selling 10,349 shares during the
BOND earns a Buy rating for its conservative risk profile and consistent inflation-beating returns. BOND benefits from active management, allowing nimble allocation into agency MBS and higher-yielding opportunities versus passive peers like BND. The normalizing yield curve and modestly widening credit spreads enhance BOND's forward return prospects and income appeal.
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer
Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy PR New